Asabys Partners

Quibim is a global leader in whole-body medical imaging analysis headquartered in Valencia, Spain. Its platform, Quibim Precision, provides an AI-first ecosystem that standardizes imaging quality, automates feature extraction, and delivers quantitative imaging biomarkers across all body parts and modalities. The system integrates deep‑learning, radiomics, and multi‑omics data to enhance disease detection, support clinical trials, and monitor treatment efficacy for pharmaceutical companies and research teams worldwide.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

Amelia Virtual Care is a mental health technology company based in Barcelona and Mountain View that specializes in developing a comprehensive virtual reality platform for the treatment of various mental health disorders, including phobias, anxiety, and depression. With a team of over 60 employees, Amelia has delivered more than 200,000 VR therapy sessions globally, primarily focusing on the United States market. The company's platform is designed to enhance mental health treatment by providing professionals with a user-friendly control panel and complete VR equipment, facilitating effective therapy sessions. Recent financing and a new management team are set to accelerate Amelia's growth and enhance its commercial presence and clinical validation within the mental health sector.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

Founded in 2018, Koa Health develops digital wellbeing and therapeutics solutions combining clinical research and advanced technologies. It offers personalized mental health support across various conditions through its platform, which includes stepped care, secure symptom tracking, prediction tools, and evidence-based activities for stress management, sleep improvement, relaxation, positive thinking, and self-confidence enhancement.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Origo Biopharma S.L. is a biotechnology company founded in 2017 and headquartered in San Cibrao das Viñas, Spain. The company focuses on the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, including cancer and fibrosis. By developing organ-restricted drugs, Origo Biopharma seeks to address unmet medical needs in these areas, providing potential cures for debilitating health conditions.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Anaconda Biomed, based in Barcelona, Spain, develops neuro-thrombectomy devices for acute ischemic stroke. Founded in 2015, the company designs and manufactures catheters and integrated thrombectomy systems, including the ANCD BRAIN, a third-generation stented aspiration thrombectomy system. Its offerings combine a delivery catheter, aspiration catheter, and a stent retriever to provide mechanical thrombectomy with thrombus extraction, aiming to remove clots and reduce stroke-related complications. The firm focuses on advancing minimally invasive solutions to treat AIS.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Amelia Virtual Care is a mental health technology company based in Barcelona and Mountain View that specializes in developing a comprehensive virtual reality platform for the treatment of various mental health disorders, including phobias, anxiety, and depression. With a team of over 60 employees, Amelia has delivered more than 200,000 VR therapy sessions globally, primarily focusing on the United States market. The company's platform is designed to enhance mental health treatment by providing professionals with a user-friendly control panel and complete VR equipment, facilitating effective therapy sessions. Recent financing and a new management team are set to accelerate Amelia's growth and enhance its commercial presence and clinical validation within the mental health sector.